Track Psyence Biomedical Ltd. Common Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Psyence Biomedical Ltd. Common Shares PBM Open Psyence Biomedical Ltd. Common Shares in new tab

4.47 USD
P/E
0.04
EPS
-389.98
P/B
0.12
ROE
-74.29
Beta
1.79
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
P/E0.04
EPS-389.98
Book Value39.62
Price to Book0.12
% Insiders4.445%

DCF Valuation

Tweak assumptions to recompute fair value for Psyence Biomedical Ltd. Common Shares (PBM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Psyence Biomedical Ltd. Common Shares Logo Psyence Biomedical Ltd. Common Shares Analysis (PBM)

Healthcare Official Website Stock

Is Psyence Biomedical Ltd. Common Shares a good investment? Psyence Biomedical Ltd. Common Shares (PBM) is currently trading at 4.47 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.04. This relatively low multiple may signal that Psyence Biomedical Ltd. Common Shares is undervalued compared to historical market norms.

Investor FAQ

Does Psyence Biomedical Ltd. Common Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Psyence Biomedical Ltd. Common Shares?

Psyence Biomedical Ltd. Common Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Exchange Ticker
NASDAQ PBM

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Nov. 26, 2024 0.010000
May 5, 2025 0.120000
Jan. 20, 2026 0.160000
Feb. 2, 2026 0.170000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion